Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12676583 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Sørensen CS, et al. (2003) Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247-58 12676583
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S124-p - Cdc25A (human) ▲
Orthologous residues
Cdc25A (human): S124‑p, Cdc25A (mouse): S122‑p, Cdc25A (rat): S124‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Chk2 (human)
KINASE Chk1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
UCN-01 decrease
Downstream Regulation
 Effect of modification (function):  protein degradation

S178-p - Cdc25A (human) ▲
Orthologous residues
Cdc25A (human): S178‑p, Cdc25A (mouse): S171‑p, Cdc25A (rat): S178‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  According to dr CS Sorensen (css@cancer.dk) numbering for S178 (S177 in PSDB) in the paper relates to sequence #AF527417.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Chk1 (human)
KINASE Chk2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UCN-01 decrease
ionizing radiation increase
Downstream Regulation
 Effect of modification (function):  protein degradation

S279-p - Cdc25A (human) ▲
Orthologous residues
Cdc25A (human): S279‑p, Cdc25A (mouse): S271‑p, Cdc25A (rat): S283‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Chk1 (human)
KINASE Chk2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UCN-01 decrease
ionizing radiation increase
Downstream Regulation
 Effect of modification (function):  protein degradation

S293-p - Cdc25A (human) ▲
Orthologous residues
Cdc25A (human): S293‑p, Cdc25A (mouse): S284‑p, Cdc25A (rat): S296‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  U2OS (bone cell) [GR (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Chk1 (human)
KINASE Chk2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Chk1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UCN-01 decrease
ionizing radiation increase
Downstream Regulation
 Effect of modification (function):  protein degradation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.